JP2025510910A5 - - Google Patents
Info
- Publication number
- JP2025510910A5 JP2025510910A5 JP2024557179A JP2024557179A JP2025510910A5 JP 2025510910 A5 JP2025510910 A5 JP 2025510910A5 JP 2024557179 A JP2024557179 A JP 2024557179A JP 2024557179 A JP2024557179 A JP 2024557179A JP 2025510910 A5 JP2025510910 A5 JP 2025510910A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutically acceptable
- acceptable salt
- egfr tki
- methyl
- egfr
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263325861P | 2022-03-31 | 2022-03-31 | |
| US63/325,861 | 2022-03-31 | ||
| PCT/EP2023/058261 WO2023187037A1 (en) | 2022-03-31 | 2023-03-30 | Epidermal growth factor receptor (egfr) tyrosine kinase inhibitors in combination with an akt inhibitor for the treatment of cancer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2025510910A JP2025510910A (ja) | 2025-04-15 |
| JP2025510910A5 true JP2025510910A5 (enExample) | 2026-04-08 |
Family
ID=86007676
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024557179A Pending JP2025510910A (ja) | 2022-03-31 | 2023-03-30 | 癌の処置のための、ａｋｔ阻害剤との組み合わせにおける上皮成長因子受容体（ｅｇｆｒ）チロシンキナーゼ阻害剤 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20250205233A1 (enExample) |
| EP (1) | EP4499102A1 (enExample) |
| JP (1) | JP2025510910A (enExample) |
| KR (1) | KR20240168418A (enExample) |
| CN (1) | CN119278041A (enExample) |
| AU (1) | AU2023246862A1 (enExample) |
| CA (1) | CA3255389A1 (enExample) |
| IL (1) | IL315848A (enExample) |
| MX (1) | MX2024011959A (enExample) |
| TW (1) | TW202408514A (enExample) |
| WO (1) | WO2023187037A1 (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CR20250538A (es) * | 2023-05-26 | 2026-04-21 | Astrazeneca Ab | Composiciones farmacéuticas |
| KR20260024838A (ko) * | 2024-08-14 | 2026-02-23 | 경희대학교 산학협력단 | 프로토사파닌 b 및 오시머티닙을 유효성분으로 포함하는 폐암의 예방 또는 치료용 조성물 |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE446955T1 (de) | 1995-03-30 | 2009-11-15 | Pfizer Prod Inc | Chinazolinone derivate |
| GB9508538D0 (en) | 1995-04-27 | 1995-06-14 | Zeneca Ltd | Quinazoline derivatives |
| DE10063435A1 (de) | 2000-12-20 | 2002-07-04 | Boehringer Ingelheim Pharma | Chinazolinderviate,diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung |
| HRP20110958T1 (hr) | 2004-05-06 | 2012-01-31 | Warner-Lambert Company Llc | 4-fenilaminokinazolin-6-ilamidi |
| TW200736260A (en) | 2005-11-10 | 2007-10-01 | Smithkline Beecham Corp | Inhibitors of Akt activity |
| UA95641C2 (xx) | 2006-07-06 | 2011-08-25 | Эррей Биофарма Инк. | Гідроксильовані піримідильні циклопентани як інгібітори акт протеїнкінази$гидроксилированные пиримидильные циклопентаны как ингибиторы акт протеинкиназы |
| UY30892A1 (es) | 2007-02-07 | 2008-09-02 | Smithkline Beckman Corp | Inhibidores de la actividad akt |
| BRPI0818533B8 (pt) | 2007-10-11 | 2021-05-25 | Astrazeneca Ab | composto, composição farmacêutica, uso de um composto, e, processo para a preparação de um composto |
| US8481503B2 (en) * | 2009-03-06 | 2013-07-09 | Merck Sharp & Dohme Corp. | Combination cancer therapy with an AKT inhibitor and other anticancer agents |
| US8383607B2 (en) | 2010-03-31 | 2013-02-26 | Aeterna Zentaris Gmbh | Perifosine and capecitabine as a combined treatment for cancer |
| US20130072507A1 (en) * | 2010-05-21 | 2013-03-21 | Glaxosmithkline Llc | Combination |
| DK3686193T3 (da) | 2011-07-27 | 2022-05-30 | Astrazeneca Ab | 2-(2,4,5-substitueret anilino)pyrimidinforbindelser |
| SG11201401953WA (en) | 2011-10-31 | 2014-09-26 | Betta Pharmaceuticals Co Ltd | Methods of preparing icotinib and icotinib hydrochloride, and intermediates thereof |
| US9034885B2 (en) | 2012-01-13 | 2015-05-19 | Acea Biosciences Inc. | EGFR modulators and uses thereof |
| LT2964638T (lt) | 2013-03-06 | 2017-12-27 | Astrazeneca Ab | Epidermio augimo faktoriaus receptoriaus aktyvinančių mutacijų formų chinazolino inhibitoriai |
| ES3069593T3 (en) | 2013-08-23 | 2026-06-09 | Neupharma Inc | Quinazolin-8-yl derivatives for use in methods of treating melanoma, non-small cell lung cancer, thyroid cancer, ovarian cancer, or colon cancer |
| GB201400034D0 (en) | 2014-01-02 | 2014-02-19 | Astrazeneca Ab | Pharmaceutical Compositions comprising AZD9291 |
| US20170166598A1 (en) | 2014-05-13 | 2017-06-15 | Ariad Pharmaceuticals, Inc. | Heteroaryl compounds for kinase inhibition |
| CN105315259B (zh) | 2014-07-29 | 2018-03-09 | 上海艾力斯医药科技有限公司 | 吡啶胺基嘧啶衍生物、其制备方法及应用 |
| EP3205650B1 (en) | 2014-10-11 | 2021-08-04 | Shanghai Hansoh Biomedical Co., Ltd. | Egfr inhibitor, and preparation and application thereof |
| EP3929190B1 (en) | 2014-10-13 | 2024-12-25 | Yuhan Corporation | Compounds and compositions for modulating egfr mutant kinase activities |
| CN111170998B (zh) | 2014-11-05 | 2023-04-11 | 益方生物科技(上海)股份有限公司 | 嘧啶或吡啶类化合物、其制备方法和医药用途 |
| AU2015360360B2 (en) | 2014-12-11 | 2020-06-25 | Beta Pharma (Shanghai) Co., Ltd. | Substituted 2-anilinopyrimidine derivatives as EGFR modulators |
| CN107614503B (zh) | 2015-04-29 | 2020-03-10 | 广东众生药业股份有限公司 | 稠环或三环芳基嘧啶化合物用作激酶抑制剂 |
| WO2019126739A1 (en) * | 2017-12-21 | 2019-06-27 | Shepherd Therapeutics, Inc. | Pyrvinium pamoate anti-cancer therapies |
| WO2023035223A1 (zh) * | 2021-09-10 | 2023-03-16 | 上海艾力斯医药科技股份有限公司 | 药物组合物及其用途 |
-
2023
- 2023-03-30 CN CN202380042347.XA patent/CN119278041A/zh active Pending
- 2023-03-30 AU AU2023246862A patent/AU2023246862A1/en active Pending
- 2023-03-30 JP JP2024557179A patent/JP2025510910A/ja active Pending
- 2023-03-30 US US18/851,158 patent/US20250205233A1/en active Pending
- 2023-03-30 EP EP23717063.4A patent/EP4499102A1/en active Pending
- 2023-03-30 WO PCT/EP2023/058261 patent/WO2023187037A1/en not_active Ceased
- 2023-03-30 IL IL315848A patent/IL315848A/en unknown
- 2023-03-30 CA CA3255389A patent/CA3255389A1/en active Pending
- 2023-03-30 KR KR1020247035963A patent/KR20240168418A/ko active Pending
- 2023-03-31 TW TW112112431A patent/TW202408514A/zh unknown
-
2024
- 2024-09-27 MX MX2024011959A patent/MX2024011959A/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023529812A5 (enExample) | ||
| US8278300B2 (en) | Use for PDE5 inhibitors | |
| JP2025508703A5 (enExample) | ||
| JP2020504136A5 (enExample) | ||
| JP2025072429A (ja) | 骨髄増殖性腫瘍を治療する方法 | |
| JP2007522200A (ja) | 非定型抗精神病薬とコルチコトロピン放出因子拮抗薬の治療的組合せ | |
| JP2001097889A (ja) | Ｃｒｆアンタゴニストおよび関連組成物の使用 | |
| JP2024539852A (ja) | がんの治療のためのキナゾリノン化合物の新規使用 | |
| EP4000624A1 (en) | Btk inhibitors for treating splenomegaly | |
| JP2006528229A (ja) | Ｐｄｅ４阻害剤及びｐｄｅ５阻害剤を含有する組成物 | |
| JP2021501140A5 (enExample) | ||
| JP2025516543A5 (enExample) | ||
| US20250205233A1 (en) | Epidermal growth factor receptor (egfr) tyrosine kinase inhibitors in combination with an akt inhibitor for the treatment of cancer | |
| JP2005527583A (ja) | メラトニンを含む医薬製剤 | |
| US11642343B2 (en) | Methods of treating splenomegaly | |
| EP2313097B1 (en) | Therapeutic combination comprising an aurora kinase inhibitor and antiproliferative agents | |
| JP2001354589A (ja) | 血液透析中の血圧の安定化法 | |
| HK40078282A (en) | Btk inhibitors for treating splenomegaly | |
| WO2025179032A1 (en) | Methods of treating myelofibrosis | |
| CN120202006A (zh) | 卡帕塞替尼和维奈托克的治疗组合 | |
| MXPA06009271A (en) | Therapeutic combinations of atypical antipsychotics with corticotropin releasing factor antagonists |